Amplified in breast cancer 1 expression in breast cancer

Histopathology

Volumn 53, Issue 6, 2008, Pages 634-641

  Thorat, M A ^a   Turbin, D ^b   Morimiya, A ^a   Leung, S ^b   Zhang, Q ^c   Jeng, M H ^c   Huntsman, D G ^b   Nakshatri, H ^c,d   Badve, S ^a,c  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WALTHER CANCER INSTITUTE   (United States)

Author keywords

Amplified in breast cancer 1; Breast cancer; Human epidermal growth factor receptor 2; Oestrogen receptor; Prognosis; Steroid receptor co activator 3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR COACTIVATOR 3;

ARTICLE; BREAST CANCER; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HISTONE ACETYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SURVIVAL ANALYSIS; TRANS-ACTIVATORS;

EID: 57049128680     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03155.x     Document Type: Article

References (37)

1. Gradishar WJ. Tamoxifen - what next? Oncologist 2004 9 378 384.
2. Jackson TA, Richer JK, Bain DL et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 1997 11 693 705.
3. Shiau AK, Barstad D, Loria PM et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998 95 927 937.
4. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 1997 11 657 666.
5. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995 10 2435 2446.
6. Ali S, Metzger D, Bornert JM et al. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 1993 12 1153 1160.
7. Arnold SF, Obourn JD, Jaffe H, Notides AC. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol. Endocrinol. 1994 8 1208 1214.
8. Bunone G, Briand PA, Miksicek RJ et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996 15 2174 2183.
9. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995 270 1491 1494.
10. Martini PGV, Katzenellenbogen BS. Modulation of estrogen receptor activity by selective coregulators. J. Steroid Biochem. Mol. Biol. 2003 85 117 122.
11. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 2003 9 447S 454.
12. Tamrazi A, Carlson KE, Rodriguez AL, Katzenellenbogen JA. Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. Mol. Endocrinol. 2005 19 1516 1528.
13. Tsai MJ, Omalley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994 63 451 486.
14. Takimoto GS, Graham JD, Jackson TA et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J. Steroid Biochem. Mol. Biol. 1999 69 45 50.
15. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 2000 20 5041 5047.
16. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 2004 96 926 935.
17. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003 12 362 367.
18. Anzick SL, Kononen J, Walker RL et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997 277 965 968.
19. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res. Treat. 2001 68 21 28.
20. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999 20 321 344.
21. Bautista S, Valles H, Walker RL et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 1998 4 2925 2929.
22. Murphy LC, Simon SLR, Parkes A et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res. 2000 60 6266 6271.
23. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 2003 95 353 361.
24. Kirkegaard T, McGlynn LM, Campbell FM et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 2007 13 1405 1411.
25. Sutherland BW, Kucab J, Wu J et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005 24 4281 4292.
26. Badve S, Turbin D, Thorat MA et al. FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin. Cancer Res. 2007 13 4415 4421.
27. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004 10 7252 7259.
28. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 2001 61 903 907.
29. Harigopal M, Heymann J, Camp RL, Rimm DL. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray (TMA) and association with patient outcome. United States and Canadian Academy of Pathology: 96th Annual Meeting. San Diego, CA, USA, 2007 [abstract 137].
30. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl Cancer Inst. 2003 95 142 153.
31. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst. 2005 97 1254 1261.
32. Wu R-C, Smith CL, O'Malley BW. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev. 2005 26 393 399.
33. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. [Erratum appears in Lancet 2002; 360 (9344); 1520]. Lancet 2002 359 2131 2139.
34. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004 350 1081 1092.
35. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003 349 1793 1802.
36. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC Trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 2005 23 7512 7517.
37. Arpino G, Gutierrez C, Weiss H et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl Cancer Inst. 2007 99 694 705.